Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Controlled Trial ◽

Metastatic Breast ◽

Final Analysis ◽

Phase 3 ◽

Double Blind ◽

Hormone Receptor Positive ◽

Faculty Opinions recommendation of Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726198033.793559052 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Controlled Trial ◽

Metastatic Breast ◽

Final Analysis ◽

Phase 3 ◽

Double Blind ◽

Hormone Receptor Positive ◽

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30088-8 ◽

2017 ◽

Vol 18 (3) ◽

pp. 371-383 ◽

Cited By ~ 21

Author(s):

Pin Zhang ◽

Tao Sun ◽

Qingyuan Zhang ◽

Zhongyu Yuan ◽

Zefei Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Controlled Trial ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Heavily Pretreated ◽

Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy

10.1158/0008-5472.sabcs13-ot3-2-10 ◽

2013 ◽

Cited By ~ 2

Author(s):

N Turner ◽

F André ◽

S Loibl ◽

J Ro ◽

H Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive

Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial

Annals of Oncology ◽

10.1016/j.annonc.2020.10.600 ◽

2020 ◽

Author(s):

B. Xu ◽

T. Sun ◽

Q. Zhang ◽

P. Zhang ◽

Z. Yuan ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Controlled Trial ◽

Metastatic Breast ◽

Final Analysis ◽

Phase Iii ◽

Heavily Pretreated ◽

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL

Annals of Oncology ◽

10.1016/j.annonc.2020.12.013 ◽

2020 ◽

Author(s):

M. Martin ◽

C. Zielinski ◽

M. Ruiz-Borrego ◽

E. Carrasco ◽

N. Turner ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Controlled Trial ◽

Metastatic Breast ◽

Phase Iii ◽

Epidermal Growth ◽

Effects of a nurse-led medication self-management programme in women with oral treatments for metastatic breast cancer: A mixed-method randomised controlled trial

European Journal of Oncology Nursing ◽

10.1016/j.ejon.2020.101780 ◽

2020 ◽

Vol 47 ◽

pp. 101780

Author(s):

Hiroko Komatsu ◽

Kaori Yagasaki ◽

Takuhiro Yamaguchi ◽

Ayako Mori ◽

Hiromi Kawano ◽

...

Keyword(s):

Breast Cancer ◽

Mixed Method ◽

Controlled Trial ◽

Metastatic Breast ◽

Management Programme ◽

Self Management ◽

Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy

10.1158/1538-7445.sabcs15-p4-13-03 ◽

2016 ◽

Cited By ~ 1

Author(s):

S Verma ◽

AM DeMichele ◽

S Loi ◽

J Ro ◽

M Colleoni ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Hormone Receptor Positive

1815 A double blind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes

European Journal of Cancer ◽

10.1016/s0959-8049(16)30767-5 ◽

2015 ◽

Vol 51 ◽

pp. S270-S271 ◽

Cited By ~ 3

Author(s):

N. Harbeck ◽

M. Cristofanilli ◽

J. Ro ◽

F. André ◽

S. Loi ◽

...

Keyword(s):

Breast Cancer ◽

Patient Reported Outcomes ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Hormone Receptor Positive ◽

Menopausal Women ◽

Patient Reported ◽

Post Menopausal

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00135-7 ◽

2015 ◽

Vol 16 (13) ◽

pp. 1380-1388 ◽

Cited By ~ 171

Author(s):

Rajendra Badwe ◽

Rohini Hawaldar ◽

Nita Nair ◽

Rucha Kaushik ◽

Vani Parmar ◽

...

Keyword(s):

Breast Cancer ◽

Controlled Trial ◽

Primary Tumour ◽

Metastatic Breast ◽

Open Label ◽

Locoregional Treatment ◽

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30702-6 ◽

2021 ◽

Vol 22 (3) ◽

pp. 351-360

Author(s):

Binghe Xu ◽

Min Yan ◽

Fei Ma ◽

Xichun Hu ◽

Jifeng Feng ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽